CJC-1295 and Ipamorelin Stack: The Complete Guide (2026)

What Is the CJC-1295 + Ipamorelin Stack?

The CJC-1295 and ipamorelin stack is one of the most widely used peptide combinations in modern anti-aging and performance medicine. These two peptides work through distinct but complementary mechanisms to amplify the body's natural growth hormone (GH) output — without the side effect burden of exogenous human growth hormone (rhGH).

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells your pituitary to release GH. Ipamorelin is a growth hormone secretagogue (GHS) that mimics ghrelin to stimulate GH release through an entirely different receptor pathway. When combined, they produce a synergistic GH pulse estimated to be 3–5 times larger than GHRH alone — with a simultaneous IGF-1 elevation 20–30% higher than either compound used solo.

This guide covers everything you need to know: how each peptide works, why the stack is superior to either alone, evidence-based dosing protocols, clinical benefits, side effects, and safety considerations.

CJC-1295: The GHRH Analog Explained

Mechanism of Action

CJC-1295 is a modified form of GHRH(1-29) — the first 29 amino acids of natural growth hormone-releasing hormone, with four amino acid substitutions that prevent it from being rapidly degraded by an enzyme called dipeptidyl peptidase IV (DPP-IV). This single modification transforms a peptide that would last minutes in the bloodstream into one that can persist for hours or days.

Once injected, CJC-1295 binds to GHRH receptors on pituitary somatotroph cells. This activates adenylate cyclase, increases intracellular cAMP, and stimulates GH synthesis and release. Critically, CJC-1295 increases the amplitude of GH pulses — meaning each pulse is more powerful — rather than simply triggering more pulses.

CJC-1295 With DAC vs. Without DAC

CJC-1295 comes in two versions, and the distinction matters significantly:

• CJC-1295 Without DAC (Modified GRF 1-29 / Mod GRF 1-29): Half-life of approximately 30–60 minutes. Produces a discrete GH spike that resolves within 2–3 hours. Dosed 1–3 times daily. Most commonly used in stacks because the timing aligns well with ipamorelin's short-acting profile.
• CJC-1295 With DAC (Drug Affinity Complex): The DAC technology allows the peptide to covalently bind to albumin after injection — extending its half-life to an estimated 5.8–8.1 days. Produces sustained GH/IGF-1 elevation. Dosed once or twice weekly. Causes more water retention due to prolonged GH exposure.

Clinical Pharmacokinetic Data

The pivotal human clinical study by Teichman et al. (2006), published in the Journal of Clinical Endocrinology & Metabolism, established CJC-1295's remarkable pharmacodynamic profile in healthy adults:

• A single injection produced 2- to 10-fold increases in mean plasma GH lasting 6 days or longer
• Mean plasma IGF-1 increased 1.5- to 3-fold and remained elevated for 9–11 days
• After multiple doses, mean IGF-1 levels remained above baseline for up to 28 days
• No serious adverse reactions were reported at standard doses

These numbers — sustained IGF-1 elevation for nearly a month from a single injection — illustrate why CJC-1295 became a cornerstone of peptide therapy protocols.

Ipamorelin: The First Selective Growth Hormone Secretagogue

Mechanism of Action

Ipamorelin is a synthetic pentapeptide — just five amino acids — that acts as a ghrelin receptor agonist (GHS-R1a agonist). It mimics the action of ghrelin, the gut-derived "hunger hormone" that also signals the pituitary to release GH. However, unlike ghrelin itself, ipamorelin's effects on the pituitary are highly selective.

Where CJC-1295 increases GH pulse amplitude via cAMP, ipamorelin works through a calcium-dependent pathway to increase GH pulse frequency. It also reduces somatostatin tone — somatostatin being the "GH brake" that normally inhibits pituitary output between pulses. By lowering this inhibition, ipamorelin makes the pituitary more responsive to incoming GHRH signals.

What Makes Ipamorelin Unique: Selectivity

The landmark study by Raun et al. (1998), published in the European Journal of Endocrinology, established ipamorelin as a category-defining molecule and earned it the title of "the first selective growth hormone secretagogue."

The critical finding: ipamorelin did not significantly elevate ACTH, cortisol, aldosterone, prolactin, FSH, LH, or TSH — even at doses more than 200 times higher than the ED50 for GH release. This stands in sharp contrast to older GHRPs:

• GHRP-6: Potently stimulates cortisol and prolactin alongside GH
• GHRP-2: Significant cortisol/ACTH stimulation at higher doses
• Ipamorelin: GH release only, with a near-clean hormonal profile

This selectivity is why ipamorelin has largely replaced older GHRPs in clinical peptide protocols. You get the GH pulse without the cortisol spike, unwanted prolactin elevation, or intense hunger associated with GHRP-6.

Ipamorelin's half-life is approximately 1.5–2.5 hours, producing a rapid, clean GH spike that resolves within 2–3 hours of injection.

Why the Stack Is Superior: Dual-Pathway Synergy

The reason CJC-1295 and ipamorelin are almost always used together rather than alone comes down to receptor biology. The two peptides activate completely separate, non-overlapping signaling pathways:

When both pathways are activated simultaneously:

• The pituitary receives two independent stimulatory signals at once
• Ipamorelin suppresses somatostatin, removing the brakes just as CJC-1295 is pressing the accelerator
• The resulting GH pulse is estimated to be 3–5 times larger than from CJC-1295 alone
• IGF-1 elevation is approximately 20–30% higher than from either peptide solo

Think of it this way: CJC-1295 provides the sustained "base layer" of elevated GH/IGF-1 lasting days to weeks. Ipamorelin provides the acute "spike" on top of that base — a rapid 2-hour GH surge. Together, you get both breadth and depth of GH optimization.

Benefits: What the Research Shows

Fat Loss

Growth hormone directly stimulates lipolysis — the breakdown of stored fat — particularly visceral and abdominal fat. This mechanism is IGF-1-independent; GH acts directly on adipocytes via GH receptors.

A 2024 prospective study (n=48, 12 months) in adults aged 40–65 using CJC-1295/ipamorelin showed 10–15% reductions in visceral fat over the treatment course. Broader meta-analyses of GH therapy consistently show fat mass reductions of 1–2.5+ kg over 12-week periods, with greater results in longer studies combined with lifestyle optimization.

Lean Muscle Mass

IGF-1, produced primarily in the liver in response to elevated GH, drives protein synthesis, satellite cell activation, and muscle fiber growth. Meta-analyses of GH therapy show statistically significant lean body mass increases (p<0.01). For individuals using CJC-1295/ipamorelin, typical outcomes range from 3–8 lbs of lean mass gain over a full treatment course, with results most pronounced in GH-deficient individuals.

Unlike exogenous rhGH, which suppresses endogenous GH production through negative feedback, CJC-1295 and ipamorelin work through the pituitary's own regulatory systems — preserving natural pulsatility and the body's built-in safety mechanisms.

Sleep Quality

Approximately 70% of GH pulses in adults coincide with slow-wave sleep (stages III and IV). The relationship is bidirectional: better slow-wave sleep means more GH; more GHRH signaling (mimicked by CJC-1295) means better sleep quality.

A randomized, double-blind, placebo-controlled trial published in Sleep Medicine (2025) found that bedtime administration of CJC-1295/ipamorelin increased slow-wave sleep duration by 23%. Ghrelin receptor activation (mimicked by ipamorelin) has independently been shown to enhance delta-wave activity during the second half of the night.

Most users report noticeably improved sleep quality within the first 2–4 weeks of starting the stack.

Recovery and Tissue Repair

GH stimulates collagen synthesis in human tendons and skeletal muscle. IGF-1 promotes satellite cell proliferation and differentiation critical for muscle regeneration. A 2020 pilot study found that GH elevation preserved quadriceps strength in patients following ACL reconstructive surgery.

CJC-1295/ipamorelin is frequently combined with tissue-repair peptides like BPC-157 and TB-500 in clinical protocols targeting injury healing, post-surgical recovery, and musculoskeletal repair.

Anti-Aging and Longevity

GH and IGF-1 decline roughly 14% per decade after age 30 — a process known as somatopause. This age-related decline is linked to loss of skin collagen, reduced bone density, decreased energy metabolism, impaired cardiac function, and cognitive decline.

The CJC-1295/ipamorelin stack is increasingly used in longevity medicine as a more conservative, physiologically-regulated alternative to exogenous rhGH. By stimulating the pituitary to produce GH naturally — rather than bypassing it entirely with injected hormone — the stack maintains feedback regulation and avoids the supraphysiologic GH levels associated with exogenous therapy risks.

Dosing Protocols and Timing

Standard Dosing

The most commonly used protocol in clinical and research settings:

• CJC-1295 (no DAC): 100–300 mcg per injection
• Ipamorelin: 100–300 mcg per injection
• Ratio: 1:1 (matched doses)
• Frequency: Once daily (pre-bed) or twice daily (morning fasted + pre-bed)

Timing: Why Pre-Bed Matters

The largest natural GH pulse in adults occurs within the first 1–2 hours of sleep onset, coinciding with the first slow-wave sleep episode. Injecting before bed aligns the pharmacological GH pulse with this natural circadian rhythm — amplifying rather than disrupting the body's GH pattern.

Critical rule: Both peptides should be injected in a fasted state, or at least 2 hours after the last meal. Elevated insulin from food intake suppresses GH release, significantly blunting the response to the peptides. Avoid carbohydrates and sugars around injection time.

For twice-daily protocols, the morning injection should also be taken fasted. Space injections 6–8 hours apart to minimize receptor desensitization and mimic the body's natural ultradian GH pulse rhythm.

Cycle Structure

• Weekly: 5 days on, 2 days off (typical; not universally standardized)
• Cycle length: 1–3 months on, followed by 2–3 months off
• Monitoring: IGF-1 blood tests recommended to guide dosing and confirm response

Injection Method

Both peptides are administered via subcutaneous injection:

• Use an insulin syringe (29–31 gauge, 5/16" to 1/2" needle)
• Inject into abdomen, upper thighs, or upper arms
• Rotate injection sites to minimize local reactions

Reconstitution

Both CJC-1295 and ipamorelin come as lyophilized (freeze-dried) powder:

1. Add bacteriostatic water (BAC water) slowly along the vial wall — do not inject directly onto the powder
2. Gently swirl to mix; never shake (shaking can denature the peptide)
3. Standard: 2 mg vial + 2 mL BAC water = 1 mg/mL (1,000 mcg/mL); 200 mcg dose = 0.2 mL
4. Refrigerate at 2–8°C after reconstitution; use within 28 days
5. For longer storage, freeze aliquots at -20°C; avoid repeated freeze-thaw cycles

Side Effects and Safety

CJC-1295 and ipamorelin have a well-characterized safety profile. The most common side effects are class effects shared by all GH-elevating therapies:

Water Retention (15–25% of users)

GH stimulates renal sodium retention, causing temporary fluid accumulation — puffiness in the hands, face, or ankles. This is not fat gain. It's most pronounced during the first few weeks as GH levels rise, and typically resolves as the body adapts. The with-DAC version of CJC-1295 causes more water retention due to more sustained GH elevation. Managing sodium intake and staying well hydrated helps.

Tingling or Numbness in Extremities (10–20% of users)

Fluid retention can compress peripheral nerves — particularly the median nerve — producing carpal tunnel-like tingling in the hands and fingers. This is a well-documented class effect of all GH-elevating compounds. Reducing the dose usually resolves it.

Increased Appetite (10–15% of users)

Ipamorelin activates ghrelin receptors, which can mildly increase hunger. Unlike GHRP-6 — which causes intense, uncomfortable hunger — ipamorelin's appetite stimulation is generally mild. For those seeking to increase caloric intake for muscle building, this can actually be advantageous.

Drowsiness After Injection (~10–15%)

When timed for pre-bed use, mild drowsiness following injection is common and expected — and largely the point. The sleep-promoting effects of GHRH signaling make this a feature, not a bug, when dosing is properly timed.

Injection Site Reactions (~20–30%)

Mild redness, swelling, or bruising at the injection site. Managed easily by rotating injection locations.

What to Watch For: Cortisol and Other Hormones

Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate cortisol, ACTH, prolactin, FSH, LH, or TSH — confirmed at doses over 200 times the ED50 for GH (Raun et al., 1998). CJC-1295, as a GHRH analog, also does not stimulate the HPA axis directly. The stack's cortisol profile is among the safest of any GH-stimulating protocol.

Regulatory Status

CJC-1295 and ipamorelin are not FDA-approved for human therapeutic use. They are classified as research chemicals in the United States. Their compounding and prescription through 503A/503B pharmacies have come under increasing FDA regulatory scrutiny. Always work with a licensed healthcare provider when considering any peptide therapy.

CJC-1295 + Ipamorelin vs. Exogenous rhGH: Key Differences

Understanding why many practitioners prefer this stack over injected rhGH helps clarify its clinical niche:

• Endogenous regulation: Secretagogues work through the pituitary, preserving natural feedback loops. Exogenous rhGH bypasses the pituitary entirely and suppresses endogenous GH production.
• Pulsatility: Natural GH is released in pulses. The stack mimics and amplifies this pulsatile pattern. Exogenous rhGH creates a flat, continuous elevation — a less physiological profile.
• Cost: Peptide stacks are significantly less expensive than pharmaceutical rhGH.
• Risk profile: Supraphysiologic rhGH is associated with acromegaly risk, insulin resistance, and potential oncogenic effects. Secretagogues are self-limiting — the pituitary can only release what it has synthesized.

Who May Benefit Most

Clinical applications where CJC-1295/ipamorelin is most commonly considered include:

• Adults 35+ experiencing somatopause: Declining GH/IGF-1 with associated changes in body composition, energy, and sleep quality
• Athletes and active individuals: Recovery optimization, lean muscle support, improved training adaptation
• Those with poor sleep quality: Significant slow-wave sleep enhancement documented in controlled trials
• Post-surgical or injury recovery: GH/IGF-1 axis support for collagen synthesis and tissue repair
• Longevity-focused individuals: Preserving GH/IGF-1 axis function as part of a broader anti-aging protocol

The Bottom Line

The CJC-1295 and ipamorelin stack is scientifically well-grounded. CJC-1295 amplifies GH pulse amplitude and sustains IGF-1 elevation for days; ipamorelin increases GH pulse frequency and removes somatostatin inhibition — giving the pituitary the dual signal it needs to produce a substantially larger response than either peptide alone could achieve.

The evidence base spans foundational pharmacology studies (Teichman 2006, Raun 1998), animal models, and emerging clinical data on body composition, sleep, and recovery. The safety profile — particularly ipamorelin's lack of cortisol stimulation — makes this stack more tolerable than older GHRP-based protocols.

As with any peptide therapy, this stack should be undertaken under medical supervision, with appropriate IGF-1 monitoring and realistic expectations grounded in the available evidence. For those seeking to optimize the GH/IGF-1 axis in a physiologically intelligent way, CJC-1295 + ipamorelin remains one of the most evidence-supported options available in 2026.

References

1. Teichman SL, et al. "Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295." J Clin Endocrinol Metab. 2006;91(3):799–805.
2. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552–561. PMID: 9849822.
3. Ishida J, et al. "Growth hormone secretagogues: history, mechanism of action, and clinical development." JCSM Rapid Communications. 2020.
4. Antonijevic IA, et al. "Ghrelin promotes slow-wave sleep in humans." J Sleep Res. 2002. PMID: 12388174.
5. Van der Lely AJ, et al. Body composition and quality of life in adults treated with GH therapy: systematic review and meta-analysis. NCBI Bookshelf.